COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO

被引：1
|
作者：
Salinas-Escudero, G. [1 ]
Contreras-Hernandez, I [2 ]
Mould-Quevedo, J. [3 ]
机构：
[1] Hosp Infantil Mexico Fed Gomez, Mexico City, DF, Mexico
[2] Social Secur Mexican Inst, Mexico City, DF, Mexico
[3] Pfizer Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75353-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
    Calvo Aller, Emiliano
    Maroto, Pablo
    Kreif, Noemi
    Gonzalez Larriba, Jose Luis
    Lopez-Brea, Marta
    Castellano, Daniel
    Marti, Belen
    Diaz Cerezo, Silvia
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (12): : 869 - 877
  • [32] COST-EFFECTIVENESS EVALUATION OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN KAZAKHSTAN
    Kostyuk, A.
    Nurgozhin, T.
    Mazhitov, T.
    Almadiyeva, A.
    VALUE IN HEALTH, 2014, 17 (03) : A85 - A85
  • [33] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    PLOS ONE, 2024, 19 (03):
  • [34] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [35] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS
    Klijn, S.
    Van de Wetering, G.
    Malcolm, B.
    Dale, P.
    Pompen, M.
    Stevanovic, J.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [36] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
    Liu, Tong
    Jin, Yao
    Dong, Mei
    CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
  • [37] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Jun Chen
    Gaoyun Hu
    Zhuo Chen
    Xiaomin Wan
    Chongqing Tan
    Xiaohui Zeng
    Zeneng Cheng
    Clinical Drug Investigation, 2019, 39 : 931 - 938
  • [38] The Cost-Effectiveness of Pegaspargase for First-Line Treatment of Acute Lymphoblastic Leukaemia: A Cost-Utility Analysis
    Basu, S.
    Lin, P.
    Rowntree, C.
    Saha, V.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S112 - S113
  • [39] THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS
    Basu, S.
    Lin, P. L.
    Saha, V
    VALUE IN HEALTH, 2017, 20 (09) : A444 - A444
  • [40] THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS
    Basu, S.
    Lin, P. L.
    Rowntree, C.
    Saha, V.
    HAEMATOLOGICA, 2017, 102 : 598 - 599
12345